ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
Globe Newswire (Wed, 27-May 4:30 PM ET)
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
Globe Newswire (Thu, 7-May 4:05 PM ET)
ImageneBio Secures $30 Million Private Placement to Accelerate Development of Lead Program IMG-007
Market Chameleon (Mon, 13-Apr 6:46 AM ET)
ImageneBio Secures $30 Million in Private Funding to Advance Promising OX40 Antagonist IMG-007
Market Chameleon (Mon, 13-Apr 4:25 AM ET)
ImageneBio Announces $30 Million Private Placement
Globe Newswire (Mon, 13-Apr 7:00 AM ET)
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Imagenebio trades on the NASDAQ stock market under the symbol IMA.
As of July 2, 2026, IMA stock price climbed to $5.83 with 8,133 million shares trading.
IMA has a beta of 1.35, meaning it tends to be more sensitive to market movements. IMA has a correlation of 0.05 to the broad based SPY ETF.
IMA has a market cap of $65.76 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that IMA belongs to (by Net Assets): VTI, VXF, IWC.
IMA support price is $5.48 and resistance is $6.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMA shares will trade within this expected range on the day.
